ReviewJournal of leukocyte biology2009
Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.
Review in Journal of leukocyte biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Review
- Regulation of the pyruvate metabolism node by monogene and polygene engineering of HEK-293 cells.RSC advances · 2019Article
- An HIV-1 Mini Vaccine Induced Long-lived Cellular and Humoral Immune Responses.International journal of molecular and cellular medicine · 2015Article
- Genetically modified hematopoietic stem cell transplantation for HIV-1-infected patients: can we achieve a cure?Molecular therapy : the journal of the American Society of Gene Therapy · 2014Review
- Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors.Biotechnology and bioengineering · 2012Article
- Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications.Journal of translational medicine · 2011Article
- Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Rabies virus as a research tool and viral vaccine vector.Advances in virus research · 2011Review
- Back to the future: covalent epitope-based HIV vaccine development.Expert review of vaccines · 2010Review
- Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant.Journal of virology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
An efficacious vaccine to HIV-1 is direly needed to stem the global pandemic. Immunogens that elicit broadly cross-neutralizing antibodies to HIV-1 remain elusive, and thus, most HIV-1 vaccine efforts are focusing on induction of T cells. The notion that T cells can mediate protection against HIV-1 has been called into question by the failure of the STEP trial, which was designed to test this concept by the use of an E1-deleted Ad vaccine carrier. Lack of efficacy of the STEP trial vaccine underscores our limited knowledge about correlates of immune protection against HIV-1 and stresses the need for an enhanced commitment to basic research, including preclinical and clinical vaccine studies. In this review, we discuss known correlates of protection against HIV-1 and different vaccine strategies that have been or are being explored to induce such correlates, focusing on T cell-inducing vaccines and particularly on Ad vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.